Kyverna Therapeutics Soars 10.13% on Analyst Upgrade

On May 27, 2025, Kyverna Therapeutics, Inc. saw a significant rise of 10.13% in pre-market trading, reflecting a strong bullish sentiment among investors.

Kyverna Therapeutics, a clinical-stage biopharmaceutical company, is dedicated to developing cell therapies for autoimmune diseases. The company's lead program, KYV-101, is an autologous CD19 CAR T-cell product candidate designed to treat conditions such as lupus nephritis and systemic sclerosis. Additionally, Kyverna is exploring an allogeneic, off-the-shelf approach to broaden patient access and is researching other autoimmune diseases, including inflammatory bowel disease.

On May 27, 2025, HC Wainwright & Co. analyst Mitchell Kapoor upgraded Kyverna Therapeutics' stock rating from 'Neutral' to 'Buy,' indicating a positive outlook on the company's prospects. This upgrade was accompanied by a price target increase from $4 to $5, further bolstering investor confidence in Kyverna's potential.

China Universal Asset Management Co. Ltd. acquired a new stake in Kyverna Therapeutics during the fourth quarter, valued at approximately $34,000. This investment underscores the growing interest in the company's innovative approach to treating autoimmune diseases.